ClinicalTrials.gg

Program

SIM0689

A development code. Also written as “SIM0689 for Injection”.

Its studies are mostly in Neoplasms, led by Simcere Pharmaceutical Group.

Furthest: phase 1, since Jun 10, 20261 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Simcere Pharmaceutical Group11 open or runningphase 1since Jun 10, 2026Jun 10, 2026Dec 2028phase 1 · NCT07660432

Also a collaborator on its studies: shanghai-xianwei-medical-technology-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 10, 2026First study: phase 1 study in NeoplasmsFirst studyNCT07660432 · 472 planned · China

Ahead

  1. Dec 2028Primary completion: phase 1 study in NeoplasmsNCT07660432

TargetBeta

VEGFA →read by rule
“SIM0689 for Injection is a Programmed Cell Death Protein 1(PD1) / Vascular Endothelial Growth Factor (VEGF) bispecific antibody.”study text, by rule · the study

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
BevacizumabruleHoffmann-La Rochephase 4250
RanibizumabruleNovartisphase 4108
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
suvemcitugruleSimcere Pharmaceutical Groupphase 36
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
surabgene lomparvovecAbbViephase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07660432Neoplasms · China1RecruitingDec 2028472

How it is read

Names in the registry

  • “SIM0689 for Injection”, 1 entry

Codes read as this program: SIM0689.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.